Navigation Links
Vion Pharmaceuticals to Present at 20th Annual Bear Stearns Healthcare Conference
Date:9/10/2007

is news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203)498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... 2015 The laboratory information management systems ... a number of technological advancements due to factors such ... need to integrate healthcare systems, and increasing government support ... system integration. Key players in the market focus on ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... to be a fortune teller, but he believes his ... in radiation therapy for some time to come. , ... the Hi-Art System, the company's radiation therapy platform, will ... 250,000 patient fractions, or incremental treatments, have been delivered ...
... It's not too early to gauge the level of ... company formed by Beth Donley and University of ... already is rubbing elbows with interested investors, particularly angels, ... for eventually attracting big dollars from venture capitalists involves ...
... set forth predictions for 2007 is just too hard to resist. ... the next 12 months if you'll send me yours. Mine are ... to chris@guidewiregroup.com before the end of the week). So, ... away , ,Well, not Web 2.0 the development technique to ...
Cached Biology Technology:TomoTherapy sees sustained market advantage 2TomoTherapy sees sustained market advantage 3TomoTherapy sees sustained market advantage 4UW scientist, former WiCell director found stem cell company 2UW scientist, former WiCell director found stem cell company 3Bold prediction: Web 2.0 goes away in 2007 2Bold prediction: Web 2.0 goes away in 2007 3
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
... discovery of a new molecular signature for a destructive and ... therapeutic target for the hard-to-treat condition. In a study ... atresia, researchers report in the November Journal of Clinical ... the same disease process. Some patients have a second molecular ...
... Results of a study published this week in the journal ... to move to keep up with recent climate change effects in ... The study was supported by the National Science Foundation (NSF), ... and Synthesis at the University of California at Santa Barbara. ...
... MADISON, Wisconsin, November 7, 2011 A 79-year-old ... Northern Research Station are part of a team that ... years. Dan Lindner, a research plant pathologist with ... (CFMR), is one of 13 scientists participating in the ...
Cached Biology News:Possible treatment target found for main cause of severe liver disease in kids 2Possible treatment target found for main cause of severe liver disease in kids 3One if by land, Two if by sea? Climate change 'escape routes' 2Forest Service part of team sequencing 1,000 fungal genomes 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: